Intestinal fluid volumes and transit of dosage forms as a imaging

Alimentary Pharmacology and Therapeutics 22, 971-979 DOI: 10.1111/j.1365-2036.2005.02683.x

Citation Report

#	Article	IF	CITATIONS
1	Disposition and sterol-lowering effect of ezetimibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins. Clinical Pharmacology and Therapeutics, 2006, 80, 477-485.	4.7	41
2	An Investigation into the In Vivo Performance Variability of pH Responsive Polymers for Ileo-Colonic Drug Delivery Using Gamma Scintigraphy in Humans. Journal of Pharmaceutical Sciences, 2006, 95, 2760-2766.	3.3	88
3	Disposition and Sterol-Lowering Effect of Ezetimibe in Multidrug Resistance-Associated Protein 2-Deficient Rats. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 1293-1299.	2.5	31
4	Non-invasive quantification of small bowel water content by MRI: a validation study. Physics in Medicine and Biology, 2007, 52, 6909-6922.	3.0	82
5	Pharmacokinetic simulation of biowaiver criteria: The effects of gastric emptying, dissolution, absorption and elimination rates. European Journal of Pharmaceutical Sciences, 2007, 30, 155-166.	4.0	73
6	Interplay Between Intestinal pH, Transit Time and Feed Status on the In Vivo Performance of pH Responsive Ileo-Colonic Release Systems. Pharmaceutical Research, 2008, 25, 1828-1835.	3.5	188
7	Impairment of the in vitro drug release behaviour of oral modified release preparations in the presence of alcohol. International Journal of Pharmaceutics, 2008, 360, 171-176.	5.2	39
8	Gut instincts: Explorations in intestinal physiology and drug delivery. International Journal of Pharmaceutics, 2008, 364, 213-226.	5.2	394
9	Biorelevant dissolution testing of colon-specific delivery systems activated by colonic microflora. Journal of Controlled Release, 2008, 125, 77-86.	9.9	98
10	Replacement therapy of oral hydrocortisone in adrenal insufficiency: the influence of gastrointestinal factors. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 749-758.	3.3	21
11	Bioavailability of amoxicillin and clavulanic acid from extended release tablets depends on intragastric tablet deposition and gastric emptying. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 70, 641-648.	4.3	57
12	Irregular absorption profiles observed from diclofenac extended release tablets can be predicted using a dissolution test apparatus that mimics in vivo physical stresses. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 70, 421-428.	4.3	145
14	A Review of Multimatrix System (MMX) Mesalazine in the Management of Ulcerative Colitis. Clinical Medicine Therapeutics, 2009, 1, CMT.S38.	0.1	1
15	A novel concept in enteric coating: A double-coating system providing rapid drug release in the proximal small intestine. Journal of Controlled Release, 2009, 133, 119-124.	9.9	65
16	The extended release properties of HPMC matrices in the presence of dietary sugars. Journal of Controlled Release, 2009, 138, 251-259.	9.9	46
17	Fabrication and in vivo evaluation of highly pH-responsive acrylic microparticles for targeted gastrointestinal delivery. European Journal of Pharmaceutical Sciences, 2009, 37, 284-290.	4.0	42
18	Comparison of dissolution profiles obtained from nifedipine extended release once a day products using different dissolution test apparatuses. European Journal of Pharmaceutical Sciences, 2009, 38, 147-155.	4.0	62
19	Evaluation of intestinal absorption and mucosal toxicity using two promoters. II. Rat instillation and perfusion studies. European Journal of Pharmaceutical Sciences, 2009, 38, 301-3 <u>1</u> 1.	4.0	32

#	Article	IF	CITATIONS
20	Evaluation of intestinal absorption enhancement and local mucosal toxicity of two promoters. I. Studies in isolated rat and human colonic mucosae. European Journal of Pharmaceutical Sciences, 2009, 38, 291-300.	4.0	46
21	Postprandial Evolution in Composition and Characteristics of Human Duodenal Fluids in Different Nutritional States. Journal of Pharmaceutical Sciences, 2009, 98, 1177-1192.	3.3	112
22	Meal-Induced Acceleration of Tablet Transit Through the Human Small Intestine. Pharmaceutical Research, 2009, 26, 356-360.	3.5	85
23	Characterization of the Contents of Ascending Colon to Which Drugs are Exposed After Oral Administration to Healthy Adults. Pharmaceutical Research, 2009, 26, 2141-2151.	3.5	118
24	Estimation of effective intestinal membrane permeability considering bile micelle solubilisation. International Journal of Pharmaceutics, 2009, 368, 116-122.	5.2	73
25	Scintigraphic evaluation of colon targeting pectin–HPMC tablets in healthy volunteers. International Journal of Pharmaceutics, 2009, 370, 144-150.	5.2	43
26	Predicting Pharmacokinetics of Drugs Using Physiologically Based Modeling—Application to Food Effects. AAPS Journal, 2009, 11, 45-53.	4.4	139
27	Role of Physiological Intestinal Water in Oral Absorption. AAPS Journal, 2009, 11, 277-285.	4.4	70
28	Population-Based Mechanistic Prediction of Oral Drug Absorption. AAPS Journal, 2009, 11, 225-237.	4.4	365
29	Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic. Advanced Drug Delivery Reviews, 2009, 61, 1427-1449.	13.7	195
30	Toward an Increased Understanding of the Barriers to Colonic Drug Absorption in Humans: Implications for Early Controlled Release Candidate Assessment. Molecular Pharmaceutics, 2009, 6, 60-73.	4.6	114
31	Ethanolâ^'Drug Absorption Interaction: Potential for a Significant Effect on the Plasma Pharmacokinetics of Ethanol Vulnerable Formulations. Molecular Pharmaceutics, 2009, 6, 1429-1440.	4.6	47
32	Colonic treatments and targets: issues and opportunities. Journal of Drug Targeting, 2009, 17, 335-363.	4.4	78
33	Towards determining appropriate hydrodynamic conditions for in vitro in vivo correlations using computational fluid dynamics. European Journal of Pharmaceutical Sciences, 2009, 37, 291-299.	4.0	28
34	Introduction to computational oral absorption simulation. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 259-293.	3.3	108
35	Restoration of rat colonic epithelium after <i>in situ</i> intestinal instillation of the absorption promoter, sodium caprate. Therapeutic Delivery, 2010, 1, 75-82.	2.2	44
36	Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in-vivo experiments. Journal of Pharmacy and Pharmacology, 2010, 60, 63-70.	2.4	481
37	Assessment of the in-vivo drug release from pellets film-coated with a dispersion of high amylose starch and ethylcellulose for potential colon delivery. Journal of Pharmacy and Pharmacology, 2010, 62, 55-61.	2.4	17

#	Article	IF	CITATIONS
38	Dynamic Dissolution: A Step Closer to Predictive Dissolution Testing?. Molecular Pharmaceutics, 2010, 7, 1374-1387.	4.6	118
39	The transit of dosage forms through the colon. International Journal of Pharmaceutics, 2010, 395, 17-25.	5.2	53
40	Oral modified-release formulations in motion: The relationship between gastrointestinal transit and drug absorption. International Journal of Pharmaceutics, 2010, 395, 26-36.	5.2	93
41	Hydrodynamic and Species Transfer Simulations in the USP 4 Dissolution Apparatus: Considerations for Dissolution in a Low Velocity Pulsing Flow. Pharmaceutical Research, 2010, 27, 246-258.	3.5	37
42	Characterization of the Ascending Colon Fluids in Ulcerative Colitis. Pharmaceutical Research, 2010, 27, 1620-1626.	3.5	30
43	Predicting Intestinal Precipitation—A Case Example for a Basic BCS Class II Drug. Pharmaceutical Research, 2010, 27, 2119-2130.	3.5	113
44	Biorelevant Media to Simulate Fluids in the Ascending Colon of Humans and Their Usefulness in Predicting Intracolonic Drug Solubility. Pharmaceutical Research, 2010, 27, 2187-2196.	3.5	95
45	In-vitro and in-vivo erosion profiles of hydroxypropylmethylcellulose (HPMC) matrix tablets. Journal of Controlled Release, 2010, 147, 70-75.	9.9	66
46	Prediction of food effect by bile micelles on oral drug absorption considering free fraction in in intestinal fluid. European Journal of Pharmaceutical Sciences, 2010, 40, 118-124.	4.0	79
47	An investigation into the role of mucus thickness on mucoadhesion in the gastrointestinal tract of pig. European Journal of Pharmaceutical Sciences, 2010, 40, 335-341.	4.0	61
48	The transit of dosage forms through the small intestine. International Journal of Pharmaceutics, 2010, 395, 9-16.	5.2	73
49	Investigation of dissolution behavior of diclofenac sodium extended release formulations under standard and biorelevant test conditions. Drug Development and Industrial Pharmacy, 2010, 36, 518-530.	2.0	23
50	Drug Delivery. Handbook of Experimental Pharmacology, 2010, , .	1.8	29
51	Intestinal permeability and excretion into bile control the arrival of amlodipine into the systemic circulation after oral administration. Journal of Pharmacy and Pharmacology, 2010, 58, 827-836.	2.4	16
52	Colloid Formation by Drugs in Simulated Intestinal Fluid. Journal of Medicinal Chemistry, 2010, 53, 4259-4265.	6.4	72
53	Physiological Parameters for Oral Delivery and <i>in Vitro</i> Testing. Molecular Pharmaceutics, 2010, 7, 1388-1405.	4.6	364
54	Comparison of the Gastrointestinal Absorption and Bioavailability of Fenofibrate and Fenofibric Acid in Humans. Journal of Clinical Pharmacology, 2010, 50, 914-921.	2.0	43
55	A biorelevant dissolution stress test device – background and experiences. Expert Opinion on Drug	5.0	62

#	ARTICLE	IF	CITATIONS
56	magnetic imaging device and gamma scintigraphy. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 74, 84-92.	4.3	45
57	Magnetic Marker Monitoring: High resolution real-time tracking of oral solid dosage forms in the gastrointestinal tract. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 74, 93-101.	4.3	118
58	A novel double-coating approach for improved pH-triggered delivery to the ileo-colonic region of the gastrointestinal tract. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 74, 311-315.	4.3	38
59	Cytotoxicity study of ordered mesoporous silica MCM-41 and SBA-15 microparticles on Caco-2 cells. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 74, 483-494.	4.3	87
60	Predicting in vivo absorption behavior of oral modified release dosage forms containing pH-dependent poorly soluble drugs using a novel pH-adjusted biphasic in vitro dissolution test. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 76, 105-111.	4.3	77
61	Polymeric micelles for oral drug delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 76, 147-158.	4.3	332
62	Characterising the behaviour of poorly water soluble drugs in the intestine: application of biorelevant media for solubility, dissolution and transport studies. Journal of Pharmacy and Pharmacology, 2010, 62, 1656-1668.	2.4	119
63	New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs. Journal of Pharmacy and Pharmacology, 2010, 62, 1622-1636.	2.4	246
64	Improving Oral Delivery. Handbook of Experimental Pharmacology, 2010, , 345-398.	1.8	25
65	Gastric emptying of non-disintegrating solid drug delivery systems in fasted state: relevance to drug dissolution. Expert Opinion on Drug Delivery, 2010, 7, 967-976.	5.0	20
66	Evolution of a physiological pH6.8 bicarbonate buffer system: Application to the dissolution testing of enteric coated products. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 78, 151-157.	4.3	101
67	Investigation into drug release from colon-specific azoreductase-activated steroid prodrugs using in-vitro models. Journal of Pharmacy and Pharmacology, 2011, 63, 806-816.	2.4	13
68	An Oral-Controlled Release Drug Delivery System for Liquid and Semisolid Drug Formulations. AAPS PharmSciTech, 2011, 12, 1183-1185.	3.3	4
69	Bacteria and pH-Sensitive Polysaccharide-Polymer Films for Colon Targeted Delivery. Critical Reviews in Therapeutic Drug Carrier Systems, 2011, 28, 395-445.	2.2	16
70	Assessment of gastrointestinal motor functions by MRI: a comprehensive review. Neurogastroenterology and Motility, 2011, 23, 399-407.	3.0	79
71	In vivo imaging of drug delivery systems in the gastrointestinal tract. International Journal of Pharmaceutics, 2011, 417, 216-226.	5.2	50
72	Investigating the effect of solubility and density gradients on local hydrodynamics and drug dissolution in the USP 4 dissolution apparatus. International Journal of Pharmaceutics, 2011, 419, 175-185.	5.2	16
73	Mucoadhesive platforms for targeted delivery to the colon. International Journal of Pharmaceutics, 2011. 420. 11-19.	5.2	36

#	Article	IF	CITATIONS
74	Patches for improving gastrointestinal absorption: an overview. Drug Discovery Today, 2011, 16, 991-997.	6.4	18
75	Assessment of gastrointestinal pH, fluid and lymphoid tissue in the guinea pig, rabbit and pig, and implications for their use in drug development. European Journal of Pharmaceutical Sciences, 2011, 42, 3-10.	4.0	131
76	MRI Studies of the Hydrodynamics in a USP 4 Dissolution Testing Cell. Journal of Pharmaceutical Sciences, 2011, 100, 976-991.	3.3	38
77	Biopharmaceutical Characterization of Ciprofloxacin HCl–Ferrous Sulfate Interaction. Journal of Pharmaceutical Sciences, 2011, 100, 5174-5184.	3.3	19
78	Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, Part 1: Oral solutions. Journal of Pharmaceutical Sciences, 2011, 100, 5324-5345.	3.3	111
79	A novel, biodegradable and reversible polyelectrolyte platform for topical-colonic delivery of pentosan polysulphate. International Journal of Pharmaceutics, 2011, 404, 124-132.	5.2	6
80	Fraction of a dose absorbed estimation for structurally diverse low solubility compounds. International Journal of Pharmaceutics, 2011, 405, 79-89.	5.2	67
81	Modeling and mechanistic approaches for oral absorption: quality by design in action. Therapeutic Delivery, 2012, 3, 147-150.	2.2	6
82	Functional metagenomics reveals novel salt tolerance loci from the human gut microbiome. ISME Journal, 2012, 6, 1916-1925.	9.8	67
83	Soluplus-Solubilized Citrated Camptothecin—A Potential Drug Delivery Strategy in Colon Cancer. AAPS PharmSciTech, 2012, 13, 59-66.	3.3	57
84	Orally Administered Therapeutic Peptide Delivery: Enhanced Absorption Through the Small Intestine Using Permeation Enhancers. International Journal of Peptide Research and Therapeutics, 2012, 18, 259-280.	1.9	13
85	In vitro Utilization of Gold and Green Kiwifruit Oligosaccharides by Human Gut Microbial Populations. Plant Foods for Human Nutrition, 2012, 67, 200-207.	3.2	37
86	Impact of Excipient Interactions on Drug Bioavailability from Solid Dosage Forms. Pharmaceutical Research, 2012, 29, 2639-2659.	3.5	68
87	A novel liquefied gas based oral controlled release drug delivery system for liquid drug formulations. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 81, 334-338.	4.3	7
88	An In Vitro Methodology for Forecasting Luminal Concentrations and Precipitation of Highly Permeable Lipophilic Weak Bases in the Fasted Upper Small Intestine. Pharmaceutical Research, 2012, 29, 3486-3498.	3.5	79
89	Mechanistic analysis of solute transport in an <i>in vitro</i> physiological twoâ€phase dissolution apparatus. Biopharmaceutics and Drug Disposition, 2012, 33, 378-402.	1.9	77
91	Intestinal transporters for endogenic and pharmaceutical organic anions: the challenges of deriving in-vitro kinetic parameters for the prediction of clinically relevant drug–drug interactions. Journal of Pharmacy and Pharmacology, 2012, 64, 1523-1548.	2.4	30
92	Pharmaceutical Excipients Influence the Function of Human Uptake Transporting Proteins. Molecular Pharmaceutics, 2012, 9, 2577-2581.	4.6	62

#	Article	IF	CITATIONS
93	Overcoming poor permeability: translating permeation enhancers for oral peptide delivery. Drug Discovery Today: Technologies, 2012, 9, e113-e119.	4.0	74
94	Predicting the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant dissolution and transfer model tests coupled with a physiologically based pharmacokinetic model. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 82, 127-138.	4.3	69
95	The influence of gastric emptying kinetics on the drug release from enteric coated pellets in fasted state: An in vitro/in vivo correlation. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 82, 376-382.	4.3	22
97	Imaging of Gastrointestinal Absorption and Biodistribution of an Orally Administered Probe Using Positron Emission Tomography in Humans. Clinical Pharmacology and Therapeutics, 2012, 91, 653-659.	4.7	38
98	Modeling of Absorption. Methods in Molecular Biology, 2012, 929, 313-336.	0.9	3
99	Oral colon delivery of insulin with the aid of functional adjuvants. Advanced Drug Delivery Reviews, 2012, 64, 540-556.	13.7	98
100	Biorelevant in-vitro performance testing of orally administered dosage forms. Journal of Pharmacy and Pharmacology, 2012, 64, 919-930.	2.4	46
101	Dissolution testing of oral modified-release dosage forms. Journal of Pharmacy and Pharmacology, 2012, 64, 944-968.	2.4	60
102	Assessing the performance of amorphous solid dispersions. Journal of Pharmaceutical Sciences, 2012, 101, 1355-1377.	3.3	301
103	Measurement of Drug Concentration in the Stomach After Intragastric Administration of Drug Solution to Healthy Volunteers: Analysis of Intragastric Fluid Dynamics and Drug Absorption. Pharmaceutical Research, 2013, 30, 951-958.	3.5	35
104	Attenuation of glucose transport across Cacoâ€2 cell monolayers by a polyphenolâ€rich herbal extract: Interactions with SGLT1 and GLUT2 transporters. BioFactors, 2013, 39, 448-456.	5.4	53
105	A novel coating concept for ileo-colonic drug targeting: Proof of concept in humans using scintigraphy. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 84, 573-577.	4.3	39
106	Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: Case example diclofenac. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 85, 1337-1347.	4.3	49
107	NMR and MRI studies of drug delivery systems. Current Opinion in Colloid and Interface Science, 2013, 18, 214-227.	7.4	31
109	Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs. International Journal of Pharmaceutics, 2013, 453, 198-214.	5.2	465
110	In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: Application of the mechanistic absorption model GI-Sim. European Journal of Pharmaceutical Sciences, 2013, 49, 679-698.	4.0	141
111	Designing a Dynamic Dissolution Method: A Review of Instrumental Options and Corresponding Physiology of Stomach and Small Intestine. Journal of Pharmaceutical Sciences, 2013, 102, 2995-3017.	3.3	38
112	Nimodipine nanocrystals for oral bioavailability improvement: Preparation, characterization and pharmacokinetic studies. Colloids and Surfaces B: Biointerfaces, 2013, 109, 161-166.	5.0	65

#	Article	IF	CITATIONS
113	Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro–in silico–in vivo approach. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 85, 1274-1284.	4.3	58
114	Food, physiology and drug delivery. International Journal of Pharmaceutics, 2013, 457, 446-460.	5.2	100
115	Keeping a Critical Eye on the Science and the Regulation of Oral Drug Absorption: A Review. Journal of Pharmaceutical Sciences, 2013, 102, 3018-3036.	3.3	28
116	An in vitro–in silico–in vivo approach to predicting the oral pharmacokinetic profile of salts of weak acids: Case example dantrolene. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 84, 200-207.	4.3	41
117	Simulating the Postprandial Stomach: Physiological Considerations for Dissolution and Release Testing. Molecular Pharmaceutics, 2013, 10, 1610-1622.	4.6	76
118	Dynamic Analysis of Fluid Distribution in the Gastrointestinal Tract in Rats: Positron Emission Tomography Imaging after Oral Administration of Nonabsorbable Marker, [¹⁸ F]Deoxyfluoropoly(ethylene glycol). Molecular Pharmaceutics, 2013, 10, 2261-2269.	4.6	31
119	Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective. Future Virology, 2013, 8, 871-890.	1.8	10
120	Comprehensive Suppression of All Apoptosis-Induced Proliferation Pathways as a Proposed Approach to Colorectal Cancer Prevention and Therapy. PLoS ONE, 2014, 9, e115068.	2.5	22
121	Inhibition of Human Efflux Transporter ABCC2 (MRP2) by Self-emulsifying Drug Delivery System: Influences of Concentration and Combination of Excipients. Journal of Pharmacy and Pharmaceutical Sciences, 2014, 17, 447.	2.1	16
122	Novel Orally Swallowable IntelliCap® Device to Quantify Regional Drug Absorption in Human GI Tract Using Diltiazem as Model Drug. AAPS PharmSciTech, 2014, 15, 1490-1497.	3.3	70
123	Approaches to Rapid In Vivo Optimization of Hydrophilic Matrix Tablets. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , 205-232.	0.6	4
124	Beta-casein nanocarriers of celecoxib for improved oral bioavailability. European Journal of Nanomedicine, 2014, 6, .	0.6	25
125	Stimulation of colonic motility by oral <scp>PEG</scp> electrolyte bowel preparation assessed by <scp>MRI</scp> : comparison of split <i>vs</i> single dose. Neurogastroenterology and Motility, 2014, 26, 1426-1436.	3.0	44
126	PBPK models for the prediction of in vivo performance of oral dosage forms. European Journal of Pharmaceutical Sciences, 2014, 57, 300-321.	4.0	263
127	Prediction of the in vivo performance of enteric coated pellets in the fasted state under selected biorelevant dissolution conditions. European Journal of Pharmaceutical Sciences, 2014, 62, 8-15.	4.0	11
128	Predicting the oral pharmacokinetic profiles of multiple-unit (pellet) dosage forms using a modeling and simulation approach coupled with biorelevant dissolution testing: Case example diclofenac sodium. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 87, 236-243.	4.3	27
129	Resolving intraluminal drug and formulation behavior: Gastrointestinal concentration profiling in humans. European Journal of Pharmaceutical Sciences, 2014, 61, 2-10.	4.0	34
130	Influence of ageing on the gastrointestinal environment of the rat and its implications for drug delivery. European Journal of Pharmaceutical Sciences, 2014, 62, 76-85.	4.0	18

CITATION REPORT ARTICLE IF CITATIONS In vitro models for the prediction of in vivo performance of oral dosage forms. European Journal of 4.0 297 Pharmaceutical Sciences, 2014, 57, 342-366. Regional intestinal drug permeation: Biopharmaceutics and drug development. European Journal of Pharmaceutical Sciences, 2014, 57, 333-341. In vivo methods for drug absorption $\hat{a} \in Comparative physiologies, model selection, correlations with$ in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including 4.0 226 food effects. European Journal of Pharmaceutical Sciences, 2014, 57, 99-151. The influence of selenium addition during germination of <i>Brassica </i>seeds on health-promoting 2.8 potential of sprouts. International Journal of Food Sciences and Nutrition, 2014, 65, 692-702. Physical Properties in Drug Design. Topics in Medicinal Chemistry, 2014, , 1-68. 0.8 13 Development of pressure-sensitive dosage forms with a core liquefying at body temperature. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 86, 507-513. 4.3 Bio-relevant dissolution testing of hard capsules prepared from different shell materials using the dynamic open flow through test apparatus. European Journal of Pharmaceutical Sciences, 2014, 57, 4.0 29 264-272. The Biopharmaceutics Classification System: Subclasses for in vivo predictive dissolution (IPD) 4.0 258 methodology and IVIVC. European Journal of Pharmaceutical Sciences, 2014, 57, 152-163. Release Characteristics of Quetiapine Fumarate Extended Release Tablets Under Biorelevant Stress 3.3 26 Test Conditions. AAPS PharmSciTech, 2014, 15, 230-236. Development and evaluation of chitosan and chitosan/Kollicoat® Smartseal 30 D film-coated tablets 4.3 for colon targeting. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 88, 807-815. Hydrophilic Matrix Tablets for Oral Controlled Release. AAPS Advances in the Pharmaceutical 0.6 24 Sciences Series, 2014, , . Predicting the gastrointestinal behaviour of modified-release products: Utility of a novel dynamic dissolution test apparatus involving the use of bicarbonate buffers. International Journal of 5.2 Pharmaceutics, 2014, 475, 585-591 Human <i>in Vivo</i> Regional Intestinal Permeability: Importance for Pharmaceutical Drug 4.6 69 Development. Molecular Pharmaceutics, 2014, 11, 12-23. Whole body magnetic resonance imaging (MRI)., 2014, , 266-306. Formulation strategies to improve oral peptide delivery. Pharmaceutical Patent Analyst, 2014, 3, 313-336. 1.1 56 Protein Abundance of Clinically Relevant Multidrug Transporters along the Entire Length of the Human Intestine. Molecular Pharmaceutics, 2014, 11, 3547-3555. 211 Effect of Surfactants, Gastric Emptying, and Dosage Form on Supersaturation of Dipyridamole in an <i>i Nitro</i>Model Simulating the Stomach and Duodenum. Molecular Pharmaceutics, 2014, 11, 4.6 49 2835-2844. Combining in vitro and in silico methods for better prediction of surfactant effects on the

absorption of poorly water soluble drugsâ€"a fenofibrate case example. International Journal of

5.2

19

Pharmaceutics, 2014, 473, 356-365.

131

133

137

138

139

141

142

143

145

146

147

148

#	Article	IF	CITATIONS
151	Solid lipid excipients — Matrix agents for sustained drug delivery. Journal of Controlled Release, 2014, 188, 18-30.	9.9	75
152	Quantification of Gastrointestinal Liquid Volumes and Distribution Following a 240 mL Dose of Water in the Fasted State. Molecular Pharmaceutics, 2014, 11, 3039-3047.	4.6	360
153	A Case Study of In Silico Modelling of Ciprofloxacin Hydrochloride/Metallic Compound Interactions. AAPS PharmSciTech, 2014, 15, 270-278.	3.3	7
154	Evaluation of an in vitro faecal degradation method for early assessment of the impact of colonic degradation on colonic absorption in humans. European Journal of Pharmaceutical Sciences, 2014, 57, 200-206.	4.0	22
155	A simplified method to screen for in-vivo performance of oral lipid formulations. Journal of Pharmacy and Pharmacology, 2014, 66, 615-623.	2.4	17
156	Intragastric Volume Changes after Intake of a High-Caloric, High-Fat Standard Breakfast in Healthy Human Subjects Investigated by MRI. Molecular Pharmaceutics, 2014, 11, 1632-1639.	4.6	92
157	Improving outcomes in patients with adrenal insufficiency: a review of current and future treatments. Current Medical Research and Opinion, 2014, 30, 1833-1847.	1.9	20
158	Biopharmaceutical considerations and characterizations in development of colon targeted dosage forms for inflammatory bowel disease. Drug Delivery and Translational Research, 2014, 4, 187-202.	5.8	20
159	Eco-directed sustainable prescribing: feasibility for reducing water contamination by drugs. Science of the Total Environment, 2014, 493, 392-404.	8.0	61
160	Gastrointestinal transfer: In vivo evaluation and implementation in in vitro and in silico predictive tools. European Journal of Pharmaceutical Sciences, 2014, 63, 233-242.	4.0	63
161	In vitro studies of modulation of pathogenic and probiotic bacterial proliferation and adhesion to intestinal cells by blackcurrant juices. Journal of Functional Foods, 2014, 8, 35-44.	3.4	24
162	The influence of hydroxypropyl methylcellulose (HPMC) molecular weight, concentration and effect of food on in vivo erosion behavior of HPMC matrix tablets. Journal of Controlled Release, 2014, 187, 50-58.	9.9	70
163	Accelerating the dissolution of enteric coatings in the upper small intestine: Evolution of a novel pH 5.6 bicarbonate buffer system to assess drug release. International Journal of Pharmaceutics, 2014, 468, 172-177.	5.2	27
165	Impact of Luminal Fluid Volume on the Drug Absorption After Oral Administration: Analysis Based on In Vivo Drug Concentration–Time Profile in the Gastrointestinal Tract. Journal of Pharmaceutical Sciences, 2015, 104, 3120-3127.	3.3	26
166	Magnetic resonance imaging to evaluate gastrointestinal function. Neurogastroenterology and Motility, 2015, 27, 1687-1692.	3.0	21
167	Gastrointestinal pH and Transit Time Profiling in Healthy Volunteers Using the IntelliCap System Confirms Ileo-Colonic Release of ColoPulse Tablets. PLoS ONE, 2015, 10, e0129076.	2.5	95
168	Oral Absorption Promoters: Opportunities, Issues, and Challenges. Critical Reviews in Therapeutic Drug Carrier Systems, 2015, 32, 363-387.	2.2	16
169	Characterization of Contents of Distal lleum and Cecum to Which Drugs/Drug Products are Exposed During Bioavailability/Bioequivalence Studies in Healthy Adults. Pharmaceutical Research, 2015, 32, 3338-3349.	3.5	59

#	Article	IF	CITATIONS
170	pH-Dependent Liquid–Liquid Phase Separation of Highly Supersaturated Solutions of Weakly Basic Drugs. Molecular Pharmaceutics, 2015, 12, 2365-2377.	4.6	91
171	Animal Farm: Considerations in Animal Gastrointestinal Physiology and Relevance to Drug Delivery in Humans. Journal of Pharmaceutical Sciences, 2015, 104, 2747-2776.	3.3	152
172	Translating Human Effective Jejunal Intestinal Permeability to Surface-Dependent Intrinsic Permeability: a Pragmatic Method for a More Mechanistic Prediction of Regional Oral Drug Absorption. AAPS Journal, 2015, 17, 1177-1192.	4.4	20
173	Two-Stage Single-Compartment Models to Evaluate Dissolution in the Lower Intestine. Journal of Pharmaceutical Sciences, 2015, 104, 2986-2997.	3.3	15
174	Analysis of the impact of controlled release formulations on oral drug absorption, gut wall metabolism and relative bioavailability of CYP3A substrates using a physiologically-based pharmacokinetic model. European Journal of Pharmaceutical Sciences, 2015, 67, 32-44.	4.0	29
175	Coated pellets for oral colon delivery. Journal of Drug Delivery Science and Technology, 2015, 25, 1-15.	3.0	51
176	A New Physiologically Based Pharmacokinetic Model for the Prediction of Gastrointestinal Drug Absorption: Translocation Model. Drug Metabolism and Disposition, 2015, 43, 590-602.	3.3	18
177	Mammalian gastrointestinal tract parameters modulating the integrity, surface properties, and absorption of foodâ€relevant nanomaterials. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2015, 7, 609-622.	6.1	102
178	An understanding of modified release matrix tablets behavior during drug dissolution as the key for prediction of pharmaceutical product performance – case study of multimodal characterization of quetiapine fumarate tablets. International Journal of Pharmaceutics, 2015, 484, 235-245.	5.2	22
179	Colon-Targeted Oral Drug Delivery Systems: Design Trends and Approaches. AAPS PharmSciTech, 2015, 16, 731-741.	3.3	309
180	Differential inhibition features of direct-acting anti-hepatitis C virus agents against human organic anion transporting polypeptide 2B1. International Journal of Antimicrobial Agents, 2015, 46, 381-388.	2.5	8
181	Mathematical Models to Explore Potential Effects of Supersaturation and Precipitation on Oral Bioavailability of Poorly Soluble Drugs. AAPS Journal, 2015, 17, 902-917.	4.4	8
182	Analysis of small intestinal transit and colon arrival times of non-disintegrating tablets administered in the fasted state. European Journal of Pharmaceutical Sciences, 2015, 75, 131-141.	4.0	21
183	Fate, activity, and impact of ingested bacteria within the human gut microbiota. Trends in Microbiology, 2015, 23, 354-366.	7.7	474
184	In-vitro simulation of luminal conditions for evaluation of performance of oral drug products: Choosing the appropriate test media. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 93, 173-182.	4.3	152
185	Meclizine, a pregnane X receptor agonist, is a direct inhibitor and mechanism-based inactivator of human cytochrome P450 3A. Biochemical Pharmacology, 2015, 97, 320-330.	4.4	15
186	3-Hydroxyflavone and structural analogues differentially activate pregnane X receptor: Implication for inflammatory bowel disease. Pharmacological Research, 2015, 100, 64-72.	7.1	23
187	Analysis of Intra- and Intersubject Variability in Oral Drug Absorption in Human Bioequivalence Studies of 113 Generic Products. Molecular Pharmaceutics, 2015, 12, 4405-4413.	4.6	42

	Сітаті	ION REPORT	
#	Article	IF	CITATIONS
188	Application of a Bayesian approach to physiological modelling of mavoglurant population pharmacokinetics. Journal of Pharmacokinetics and Pharmacodynamics, 2015, 42, 639-657.	1.8	18
189	Investigation of pH and Temperature Profiles in the GI Tract of Fasted Human Subjects Using the Intellicap® System. Journal of Pharmaceutical Sciences, 2015, 104, 2855-2863.	3.3	324
190	Expression of Drug Transporters and Drug Metabolizing Enzymes in the Bladder Urothelium in Man and Affinity of the Bladder Spasmolytic Trospium Chloride to Transporters Likely Involved in Its Pharmacokinetics. Molecular Pharmaceutics, 2015, 12, 171-178.	4.6	29
191	Parameterization of small intestinal water volume using PBPK modeling. European Journal of Pharmaceutical Sciences, 2015, 67, 55-64.	4.0	6
192	Oral Drug Absorption. , 0, , .		6
193	Revised Estimates for the Number of Human and Bacteria Cells in the Body. PLoS Biology, 2016, 14, e1002533.	5.6	3,388
194	Development of a μDissolution-Permeation model with in situ drug concentration monitoring. Journal of Drug Delivery Science and Technology, 2016, 35, 223-233.	3.0	6
195	Electrospun Contrastâ€Agentâ€Loaded Fibers for Colonâ€Targeted MRI. Advanced Healthcare Materials, 2016, 5, 977-985.	7.6	47
196	Preparation of extended release solid dispersion formulations of tacrolimus using ethylcellulose and hydroxypropylmethylcellulose by solvent evaporation method. Journal of Pharmacy and Pharmacology, 2016, 68, 316-323.	2.4	29
197	Trospium chloride is absorbed from two intestinal "absorption windows―with different permeability in healthy subjects. International Journal of Pharmaceutics, 2016, 515, 367-373.	5.2	14
198	Navigating the human gastrointestinal tract for oral drug delivery: Uncharted waters and new frontiers. Advanced Drug Delivery Reviews, 2016, 101, 75-88.	13.7	125
199	Predicting biopharmaceutical performance of oral drug candidates – Extending the volume to dissolve applied dose concept. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 102, 191-201.	4.3	6
200	Toward Biopredictive Dissolution for Enteric Coated Dosage Forms. Molecular Pharmaceutics, 2016, 13, 1927-1936.	4.6	30
201	Age-mediated changes in the gastrointestinal tract. International Journal of Pharmaceutics, 2016, 512, 382-395.	5.2	71
202	Pharmacokinetic Study of a Diclofenac Sodium Capsule Filled with Enteric-coated Pellets in Healthy Chinese Volunteers by Liquid Chromatography-electrospray Ionization-tandem Mass Spectrometry. Drug Research, 2016, 66, 230-234.	1.7	0
203	Evaluating Oral Drug Delivery Systems: Dissolution Models. Advances in Delivery Science and Technology, 2016, , 753-771.	0.4	1
204	Biopharmaceutic classification of drugs revisited. European Journal of Pharmaceutical Sciences, 2016, 95, 82-87.	4.0	8
205	Regional Intestinal Permeability of Three Model Drugs in Human. Molecular Pharmaceutics, 2016, 13, 3013-3021.	4.6	57

#	Article	IF	CITATIONS
206	Regional Intestinal Permeability in Dogs: Biopharmaceutical Aspects for Development of Oral Modified-Release Dosage Forms. Molecular Pharmaceutics, 2016, 13, 3022-3033.	4.6	32
207	Dissolution profile of theophylline modified release tablets, using a biorelevant Dynamic Colon Model (DCM). European Journal of Pharmaceutics and Biopharmaceutics, 2016, 108, 9-17.	4.3	29
208	Resolving the physiological conditions in bioavailability and bioequivalence studies: Comparison of fasted and fed state. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 108, 214-219.	4.3	71
209	Justification of Drug Product Dissolution Rate and Drug Substance Particle Size Specifications Based on Absorption PBPK Modeling for Lesinurad Immediate Release Tablets. Molecular Pharmaceutics, 2016, 13, 3256-3269.	4.6	90
210	Exploration of Antiemetics for Osteoporosis Therapy-Induced Nausea and Vomiting Using PET Molecular Imaging Analysis to Gastrointestinal Pharmacokinetics. Pharmaceutical Research, 2016, 33, 1235-1248.	3.5	3
211	Intestinal permeation enhancers for oral peptide delivery. Advanced Drug Delivery Reviews, 2016, 106, 277-319.	13.7	266
212	Mucoadhesive microparticles for local treatment of gastrointestinal diseases. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 105, 156-165.	4.3	21
213	Effect of Castric Fluid Volume on the In Vitro Dissolution and In Vivo Absorption of BCS Class II Drugs: a Case Study with Nifedipine. AAPS Journal, 2016, 18, 981-988.	4.4	19
214	Methodology of oral formulation selection in the pharmaceutical industry. European Journal of Pharmaceutical Sciences, 2016, 87, 136-163.	4.0	52
215	Enteric-coated tablet of risedronate sodium in combination with phytic acid, a natural chelating agent, for improved oral bioavailability. European Journal of Pharmaceutical Sciences, 2016, 82, 45-51.	4.0	17
216	Meta-analysis of Magnetic Marker Monitoring Data to Characterize the Movement of Single Unit Dosage Forms Though the Gastrointestinal Tract Under Fed and Fasting Conditions. Pharmaceutical Research, 2016, 33, 751-762.	3.5	13
217	Ethanol concentrations in the human gastrointestinal tract after intake of alcoholic beverages. European Journal of Pharmaceutical Sciences, 2016, 86, 91-95.	4.0	31
218	The Influence of High Drug Loading in Xanthan Tablets and Media with Different Physiological pH and Ionic Strength on Swelling and Release. Molecular Pharmaceutics, 2016, 13, 1147-1157.	4.6	20
219	Phenolic Compounds from Fermented Berry Beverages Modulated Gene and Protein Expression To Increase Insulin Secretion from Pancreatic β-Cells in Vitro. Journal of Agricultural and Food Chemistry, 2016, 64, 2569-2581.	5.2	49
220	Development of a Unified Dissolution and Precipitation Model and Its Use for the Prediction of Oral Drug Absorption. Molecular Pharmaceutics, 2016, 13, 586-598.	4.6	41
221	Gastrointestinal Motility Variation and Implications for Plasma Level Variation: Oral Drug Products. Molecular Pharmaceutics, 2016, 13, 557-567.	4.6	34
222	Quantitative aspects of drug permeation across in vitro and in vivo barriers. European Journal of Pharmaceutical Sciences, 2016, 87, 30-46.	4.0	11
223	Comment on " <i>In Silico</i> Modeling of Gastrointestinal Drug Absorption: Predictive Performance of Three Physiologically-Based Absorption Models― Molecular Pharmaceutics, 2017, 14, 336-339.	4.6	8

#	Article	IF	CITATIONS
224	Using discrete multi-physics for detailed exploration of hydrodynamics in an in vitro colon system. Computers in Biology and Medicine, 2017, 81, 188-198.	7.0	26
225	In vitro dissolution models for the prediction of in vivo performance of an oral mesoporous silica formulation. Journal of Controlled Release, 2017, 250, 86-95.	9.9	27
226	In Vitro and In Vivo Modeling of Hydroxypropyl Methylcellulose (HPMC) Matrix Tablet Erosion Under Fasting and Postprandial Status. Pharmaceutical Research, 2017, 34, 847-859.	3.5	12
227	Colon-targeted delivery of solubilized bisacodyl by doubly enteric-coated multiple-unit tablet. European Journal of Pharmaceutical Sciences, 2017, 102, 172-179.	4.0	22
228	Unpredictable Performance of pH-Dependent Coatings Accentuates the Need for Improved Predictive <i>in Vitro</i> Test Systems. Molecular Pharmaceutics, 2017, 14, 4209-4219.	4.6	28
229	Evaluating the predictability of the in vitro transfer model and in vivo rat studies as a surrogate to investigate the supersaturation and precipitation behaviour of different Albendazole formulations for humans. European Journal of Pharmaceutical Sciences, 2017, 105, 108-118.	4.0	13
230	Ginger Extract Suppresses Inflammatory Response and Maintains Barrier Function in Human Colonic Epithelial Cacoâ€⊋ Cells Exposed to Inflammatory Mediators. Journal of Food Science, 2017, 82, 1264-1270.	3.1	30
231	Mechanistic prediction of food effects for Compound A tablet using PBPK model. Saudi Journal of Biological Sciences, 2017, 24, 603-609.	3.8	10
232	Differential activation of pregnane X receptor by carnosic acid, carnosol, ursolic acid, and rosmarinic acid. Pharmacological Research, 2017, 120, 23-33.	7.1	22
233	Exploring gastrointestinal variables affecting drug and formulation behavior: Methodologies, challenges and opportunities. International Journal of Pharmaceutics, 2017, 519, 79-97.	5.2	81
234	Considerations for the development of in vitro dissolution tests to reduce or replace preclinical oral absorption studies. European Journal of Pharmaceutical Sciences, 2017, 99, 193-201.	4.0	22
235	Prediction of Ketoconazole absorption using an updated in vitro transfer model coupled to physiologically based pharmacokinetic modelling. European Journal of Pharmaceutical Sciences, 2017, 100, 42-55.	4.0	52
236	A Review of Food–Drug Interactions on Oral Drug Absorption. Drugs, 2017, 77, 1833-1855.	10.9	116
237	Effect of Coadministered Water on the <i>In Vivo</i> Performance of Oral Formulations Containing N-Acetylcysteine: An <i>In Vitro</i> Approach Using the Dynamic Open Flow-Through Test Apparatus. Molecular Pharmaceutics, 2017, 14, 4272-4280.	4.6	9
238	Formation of hydrophobic drug nanoparticles via ambient solvent evaporation facilitated by branched diblock copolymers. International Journal of Pharmaceutics, 2017, 533, 245-253.	5.2	9
239	Antioxidant activities of ethanolic and acidic ethanolic extracts of astringent persimmon in H2O2-stimulated Caco-2 human colonic epithelial cells. Food Science and Biotechnology, 2017, 26, 1085-1091.	2.6	9
240	A novel mechanical antrum model for the prediction of the gastroretentive potential of dosage forms. International Journal of Pharmaceutics, 2017, 530, 63-70.	5.2	12
241	Whether 25 mM of metformin is achievable in human gut from a therapeutic dose of metformin?. Medical Hypotheses, 2017, 108, 51.	1.5	3

#	Article	IF	CITATIONS
242	A Multiparticulate Delivery System for Potential Colonic Targeting Using Bovine Serum Albumin as a Model Protein. Pharmaceutical Research, 2017, 34, 2663-2674.	3.5	11
243	Mechanistic Fluid Transport Model to Estimate Gastrointestinal Fluid Volume and Its Dynamic Change Over Time. AAPS Journal, 2017, 19, 1682-1690.	4.4	22
244	Magnetic Resonance Imaging Quantification of Fasted State Colonic Liquid Pockets in Healthy Humans. Molecular Pharmaceutics, 2017, 14, 2629-2638.	4.6	49
245	A review of in vivo and in vitro aspects of alcohol-induced dose dumping. AAPS Open, 2017, 3, .	1.3	13
246	Reply to "Comment on †In Silico Modeling of Gastrointestinal Drug Absorption: Predictive Performance of Three Physiologically Based Absorption Models'― Molecular Pharmaceutics, 2017, 14, 340-343.	4.6	6
247	Modified release itraconazole amorphous solid dispersion to treat Aspergillus fumigatus: importance of the animal model selection. Drug Development and Industrial Pharmacy, 2017, 43, 264-274.	2.0	6
248	A Novel Intestine Model Apparatus for Drug Dissolution Capable of Simulating the Peristaltic Action. AAPS PharmSciTech, 2017, 18, 1646-1656.	3.3	9
249	Magnetic Resonance Imaging to Visualize Disintegration of Oral Formulations. Journal of Pharmaceutical Sciences, 2017, 106, 745-750.	3.3	16
250	The dynamic gastric environment and its impact on drug and formulation behaviour. European Journal of Pharmaceutical Sciences, 2017, 96, 207-231.	4.0	73
251	Approaches to improving the oral bioavailabity of the low-permeability compound DX-9065, and species differences in bioavailability in preclinical and clinical studies. Drug Delivery System, 2017, 32, 381-388.	0.0	0
252	Oral Drug Absorption. , 2017, , 331-354.		9
253	Probiotics and Periodontal Diseases. , 0, , .		3
254	Taking the lead from our colleagues in medical education: the use of images of the in-vivo setting in teaching concepts of pharmaceutical science. Journal of Pharmaceutical Policy and Practice, 2017, 10, 22.	2.4	1
255	Orally Delivered Peptides for Treatment of Inflammatory Bowel Disease. , 2017, , 157-170.		2
256	Effects of some commonly used drinks on induction of Shiga toxin-converting prophage in Escherichia coli. Journal Fur Verbraucherschutz Und Lebensmittelsicherheit, 2018, 13, 125-129.	1.4	7
257	Determining The Pressure-Generating Capacity of The Classical and Alternative In Vitro Dissolution Methods Using a Wireless Motility Capsule. Journal of Pharmaceutical Innovation, 2018, 13, 226-236.	2.4	6
258	Interindividual and intraindividual variability of fasted state gastric fluid volume and gastric emptying of water. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 127, 309-317.	4.3	86
259	A Refined Developability Classification System. Journal of Pharmaceutical Sciences, 2018, 107, 2020-2032.	3.3	57

#	Article	IF	CITATIONS
260	Does a glucoseâ€based hydrogen and methane breath test detect bacterial overgrowth in the jejunum?. Neurogastroenterology and Motility, 2018, 30, e13350.	3.0	21
261	Pharmacokinetics of the P-gp Inhibitor Tariquidar in Rats After Intravenous, Oral, and Intraperitoneal Administration. European Journal of Drug Metabolism and Pharmacokinetics, 2018, 43, 599-606.	1.6	18
262	Measuring the Impact of Gastrointestinal Variables on the Systemic Outcome of Two Suspensions of Posaconazole by a PBPK Model. AAPS Journal, 2018, 20, 57.	4.4	19
263	Development, current applications and future roles of biorelevant two-stage in vitro testing in drug development. Journal of Pharmacy and Pharmacology, 2018, 70, 335-348.	2.4	15
264	Effects of surfactant-based permeation enhancers on mannitol permeability, histology, and electrogenic ion transport responses in excised rat colonic mucosae. International Journal of Pharmaceutics, 2018, 539, 11-22.	5.2	35
265	Investigating the Impact of Drug Crystallinity in Amorphous Tacrolimus Capsules on Pharmacokinetics and Bioequivalence Using Discriminatory InAVitro Dissolution Testing and Physiologically Based Pharmacokinetic Modeling and Simulation. Journal of Pharmaceutical Sciences, 2018, 107, 1330-1341.	3.3	53
266	Gastric Emptying and Small Bowel Water Content after Administration of Grapefruit Juice Compared to Water and Isocaloric Solutions of Glucose and Fructose: A Four-Way Crossover MRI Pilot Study in Healthy Subjects. Molecular Pharmaceutics, 2018, 15, 548-559.	4.6	58
267	Use of QSPR Modeling to Characterize In Vitro Binding of Drugs to a Gut-Restricted Polymer. Pharmaceutical Research, 2018, 35, 89.	3.5	5
268	Pulse Packet Stochastic Model for Gastric Emptying in the Fasted State: A Physiological Approach. Molecular Pharmaceutics, 2018, 15, 2107-2115.	4.6	11
269	Design, development and inÂvitro evaluation of sequentially optimized mesalamine tablets for optimum colonic delivery. Future Journal of Pharmaceutical Sciences, 2018, 4, 8-13.	2.8	1
270	Liquid Nanosize Emulsion-Filled Enteric-Coated Capsules for Colon Delivery of Immunosuppressant Peptide. AAPS PharmSciTech, 2018, 19, 881-885.	3.3	9
271	PET/CT imaging of 3D printed devices in the gastrointestinal tract of rodents. International Journal of Pharmaceutics, 2018, 536, 158-164.	5.2	78
272	Linking the Gastrointestinal Behavior of Ibuprofen with the Systemic Exposure between and within Humans—Part 2: Fed State. Molecular Pharmaceutics, 2018, 15, 5468-5478.	4.6	12
273	Stability of Vegetal Diamine Oxidase in Simulated Intestinal Media: Protective Role of Cholic Acids. Journal of Agricultural and Food Chemistry, 2018, 66, 12657-12665.	5.2	8
274	The Influence of Polymers on the Supersaturation Potential of Poor and Good Glass Formers. Pharmaceutics, 2018, 10, 164.	4.5	30
275	Mass Transport Analysis of the Enhanced Buffer Capacity of the Bicarbonate–CO ₂ Buffer in a Phase-Heterogenous System: Physiological and Pharmaceutical Significance. Molecular Pharmaceutics, 2018, 15, 5291-5301.	4.6	23
276	FIP Guidelines for Dissolution Testing of Solid Oral Products. Journal of Pharmaceutical Sciences, 2018, 107, 2995-3002.	3.3	12
277	Local delivery of macromolecules to treat diseases associated with the colon. Advanced Drug Delivery Reviews, 2018, 136-137, 2-27.	13.7	72

#	Article	IF	CITATIONS
278	Time-dependent effects on small intestinal transport by absorption-modifying excipients. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 132, 19-28.	4.3	21
279	Inhibition of Gastric H ⁺ ,K ⁺ -ATPase Activity <i>in Vitro</i> by Dissolution Media of Original Brand-Name and Generic Tablets of Lansoprazole, a Proton Pump Inhibitor. Chemical and Pharmaceutical Bulletin, 2018, 66, 896-900.	1.3	1
280	Evaluation of Using Dogs to Predict Fraction of Oral Dose Absorbed in Humans for Poorly Water-Soluble Drugs. Journal of Pharmaceutical Sciences, 2018, 107, 2489-2496.	3.3	9
281	Preclinical models for colonic absorption, application to controlled release formulation development. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 130, 247-259.	4.3	10
282	Discovery and characterization of a prevalent human gut bacterial enzyme sufficient for the inactivation of a family of plant toxins. ELife, 2018, 7, .	6.0	93
283	Gut Movements: A Review of the Physiology of Gastrointestinal Transit. Digestive Diseases and Sciences, 2018, 63, 2500-2506.	2.3	24
284	Influence of Postprandial Intragastric Pressures on Drug Release from Gastroretentive Dosage Forms. AAPS PharmSciTech, 2018, 19, 2843-2850.	3.3	14
285	Food for thought: formulating away the food effect – a PEARRL review. Journal of Pharmacy and Pharmacology, 2019, 71, 510-535.	2.4	75
286	<i>In vitro</i> methods to assess drug precipitation in the fasted small intestine – a PEARRL review. Journal of Pharmacy and Pharmacology, 2019, 71, 536-556.	2.4	39
287	Impact of Acid-Reducing Agents on Gastrointestinal Physiology and Design of Biorelevant Dissolution Tests to Reflect These Changes. Journal of Pharmaceutical Sciences, 2019, 108, 3461-3477.	3.3	25
288	In Vitro and In Vivo Test Methods for the Evaluation of Gastroretentive Dosage Forms. Pharmaceutics, 2019, 11, 416.	4.5	39
289	Magnetic Resonance Imaging Quantification of Gastrointestinal Liquid Volumes and Distribution in the Gastrointestinal Tract of Children. Molecular Pharmaceutics, 2019, 16, 3896-3903.	4.6	13
290	Intestinal absorption-modifying excipients: A current update on preclinical in vivo evaluations. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 142, 411-420.	4.3	28
291	Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part II. A mechanistic PBPK model for IR formulation comparison, proton pump inhibitor drug interactions, and administration with acidic juices. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 142, 435-448.	4.3	31
292	Improved Prediction of in Vivo Supersaturation and Precipitation of Poorly Soluble Weakly Basic Drugs Using a Biorelevant Bicarbonate Buffer in a Gastrointestinal Transfer Model. Molecular Pharmaceutics, 2019, 16, 3938-3947.	4.6	17
293	Simultaneous Quantitative Analysis of Clarithromycin and Ranitidine, Probe Inhibitors of P-Glycoprotein and OCT1, to Evaluate Potential Pharmacokinetic Influence of Potential Transporter Substrates. Chromatographia, 2019, 82, 1749-1758.	1.3	2
294	Design and characterization of a novel 3D printed pressure-controlled drug delivery system. European Journal of Pharmaceutical Sciences, 2019, 140, 105060.	4.0	28
295	In vivo characterization of enTRinsicâ,,¢ drug delivery technology capsule after intake in fed state: A cross-validation approach using salivary tracer technique in comparison to MRI. Journal of Controlled Release, 2019, 313, 24-32.	9.9	14

		15	CITATIONS
Ŧ	ARTICLE	IF	CITATIONS
296	pharmaceutical response. PharmaNutrition, 2019, 10, 100166.	1.7	9
297	The influence of different mechanical stress on the release properties of HPMC matrix tablets in sucrose-NaCl media. Journal of Drug Delivery Science and Technology, 2019, 54, 101246.	3.0	8
298	A review of the antimicrobial side of antidepressants and its putative implications on the gut microbiome. Australian and New Zealand Journal of Psychiatry, 2019, 53, 1151-1166.	2.3	43
299	Integrating Drug- and Formulation-Related Properties With Gastrointestinal Tract Variability Using a Product-Specific Particle Size Approach: Case Example Ibuprofen. Journal of Pharmaceutical Sciences, 2019, 108, 3842-3847.	3.3	21
300	Application of Permeation Enhancers in Oral Delivery of Macromolecules: An Update. Pharmaceutics, 2019, 11, 41.	4.5	111
301	Cinnamon subcritical water extract attenuates intestinal inflammation and enhances intestinal tight junction in a Caco-2 and RAW264.7 co-culture model. Food and Function, 2019, 10, 4350-4360.	4.6	30
302	Successful oral delivery of poorly water-soluble drugs both depends on the intraluminal behavior of drugs and of appropriate advanced drug delivery systems. European Journal of Pharmaceutical Sciences, 2019, 137, 104967.	4.0	222
303	"Development of Fixed Dose Combination Products―Workshop Report: Considerations of Gastrointestinal Physiology and Overall Development Strategy. AAPS Journal, 2019, 21, 75.	4.4	7
304	Natural Deep Eutectic Solvents as Agents for Improving Solubility, Stability and Delivery of Curcumin. Pharmaceutical Research, 2019, 36, 116.	3.5	122
305	Simulated, biorelevant, clinically relevant or physiologically relevant dissolution media: The hidden role of bicarbonate buffer. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 142, 8-19.	4.3	34
306	Vitamin E analogues differentially inhibit human cytochrome P450 3A (CYP3A)-mediated oxidative metabolism of lithocholic acid: Impact of δ-tocotrienol on lithocholic acid cytotoxicity. Toxicology, 2019, 423, 62-74.	4.2	5
307	Prediction Accuracy of Mechanism-Based Oral Absorption Model for Dogs. Journal of Pharmaceutical Sciences, 2019, 108, 2728-2736.	3.3	15
308	MRI of the Colon in the Pharmaceutical Field: The Future before us. Pharmaceutics, 2019, 11, 146.	4.5	12
309	Effects of the Pâ€Glycoprotein Inhibitor Clarithromycin on the Pharmacokinetics of Intravenous and Oral Trospium Chloride: A 4â€Way Crossover Drugâ€Drug Interaction Study in Healthy Subjects. Journal of Clinical Pharmacology, 2019, 59, 1319-1330.	2.0	5
310	The mechanisms of pharmacokinetic food-drug interactions – A perspective from the UNGAP group. European Journal of Pharmaceutical Sciences, 2019, 134, 31-59.	4.0	224
311	Impact of regional differences along the gastrointestinal tract of healthy adults on oral drug absorption: An UNGAP review. European Journal of Pharmaceutical Sciences, 2019, 134, 153-175.	4.0	146
312	Adjustment of triple shellac coating for precise release of bioactive substances with different physico-chemical properties in the ileocolonic region. International Journal of Pharmaceutics, 2019, 564, 472-484.	5.2	5
313	Screening for CYP3A4 inhibition and induction coupled to parallel artificial membrane permeability assay (PAMPA) for prediction of botanical-drug interactions: The case of aA§aA-and maca. Phytomedicine, 2019, 59, 152915.	5.3	3

# 314	ARTICLE Understanding the Potential for Dissolution Simulation to Explore the Effects of Medium Viscosity on Particulate Dissolution. AAPS PharmSciTech, 2019, 20, 47.	IF 3.3	CITATIONS
315	High-throughput screening of excipients with a biological effect: a kinetic study on the effects of surfactants on efflux-mediated transport. Journal of Pharmacy and Pharmacology, 2019, 71, 889-897.	2.4	15
316	Novel Drug Delivery Technologies. , 2019, , .		6
317	An In Situ Gelling System for the Local Treatment of Inflammatory Bowel Disease (IBD). The Loading of Maqui (Aristotelia Chilensis) Berry Extract as an Antioxidant and Anti-Inflammatory Agent. Pharmaceutics, 2019, 11, 611.	4.5	17
318	Automated small-scale in vitro transfer model as screening tool for the prediction of in vivo-dissolution and precipitation of poorly solubles. International Journal of Pharmaceutics, 2019, 556, 150-158.	5.2	9
319	Application of a Dynamic Fluid and pH Model to Simulate Intraluminal and Systemic Concentrations of a Weak Base in GastroPlusâ,,¢. Journal of Pharmaceutical Sciences, 2019, 108, 305-315.	3.3	32
320	Predictive PBPK modeling as a tool in the formulation of the drug candidate TMP-001. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 134, 144-152.	4.3	11
321	MRI analysis of fecal volume and dryness: Validation study using an experimental oxycodoneâ€induced constipation model. Journal of Magnetic Resonance Imaging, 2019, 50, 733-745.	3.4	7
322	Preparation and Characterization of an Oral Norethindrone Sustained Release/Controlled Release Nanoparticles Formulation Based on Chitosan. AAPS PharmSciTech, 2019, 20, 54.	3.3	9
323	Characterization of the gastrointestinal transit and disintegration behavior of floating and sinking acid-resistant capsules using a novel MRI labeling technique. European Journal of Pharmaceutical Sciences, 2019, 129, 163-172.	4.0	26
324	PBPK Absorption Modeling of Food Effect and Bioequivalence in Fed State for Two Formulations with Crystalline and Amorphous Forms of BCS 2 Class Drug in Generic Drug Development. AAPS PharmSciTech, 2019, 20, 59.	3.3	27
325	Multifunctional quercetin conjugated chitosan nano-micelles with P-gp inhibition and permeation enhancement of anticancer drug. Carbohydrate Polymers, 2019, 203, 10-18.	10.2	83
326	A Simulated Stomach Duodenum Model Predicting the Effect of Fluid Volume and Prandial Gastric Flow Patterns on Nifedipine Pharmacokinetics From Cosolvent-Based Capsules. Journal of Pharmaceutical Sciences, 2019, 108, 288-294.	3.3	5
327	The impact of food intake on the luminal environment and performance of oral drug products with a view to <i>in vitro</i> and <i>in silico</i> simulations: a PEARRL review. Journal of Pharmacy and Pharmacology, 2019, 71, 557-580.	2.4	51
328	Quantitative analysis of the effect of controlled-release formulation on nonlinear gastrointestinal absorption of P-glycoprotein substrate talinolol using physiologically based pharmacokinetic absorption model. Journal of Drug Delivery Science and Technology, 2020, 56, 101057.	3.0	5
329	Microbial Contribution to the Human Metabolome: Implications for Health and Disease. Annual Review of Pathology: Mechanisms of Disease, 2020, 15, 345-369.	22.4	104
330	Development and validation of a Level A in-vitro in-vivo correlation for tofacitinib modified-release tablets using extrudable core system osmotic delivery technology. European Journal of Pharmaceutical Sciences, 2020, 147, 105200.	4.0	13
331	ICH M9 Guideline in Development on Biopharmaceutics Classification System-Based Biowaivers: An Industrial Perspective from the IQ Consortium. Molecular Pharmaceutics, 2020, 17, 361-372.	4.6	13

#	Article	IF	CITATIONS
332	Prediction Characteristics of Oral Absorption Simulation Software Evaluated Using Structurally Diverse Low-Solubility Drugs. Journal of Pharmaceutical Sciences, 2020, 109, 1403-1416.	3.3	18
333	Absorptive Dissolution Testing: An Improved Approach to Study the Impact of Residual Crystallinity on the Performance of Amorphous Formulations. Journal of Pharmaceutical Sciences, 2020, 109, 1312-1323.	3.3	15
334	Characterization of the Hydrodynamics in the USP Basket Apparatus Using Computational Fluid Dynamics. Journal of Pharmaceutical Sciences, 2020, 109, 1231-1241.	3.3	9
335	Injection moulded controlled release amorphous solid dispersions: Synchronized drug and polymer release for robust performance. International Journal of Pharmaceutics, 2020, 575, 118908.	5.2	3
336	Unravelling the antimicrobial action of antidepressants on gut commensal microbes. Scientific Reports, 2020, 10, 17878.	3.3	77
337	Exploring the Effect of Esomeprazole on Gastric and Duodenal Fluid Volumes and Absorption of Ritonavir. Pharmaceutics, 2020, 12, 670.	4.5	15
338	Multidimensional analysis of human intestinal fluid composition. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 153, 226-240.	4.3	16
339	Mechanisms of Colorectal Cancer Prevention by Aspirin—A Literature Review and Perspective on the Role of COX-Dependent and -Independent Pathways. International Journal of Molecular Sciences, 2020, 21, 9018.	4.1	29
340	Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: OrBiTo consortium commentary. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 155, 55-68.	4.3	38
341	Modeling Invasion of Campylobacter jejuni into Human Small Intestinal Epithelial-Like Cells by Bayesian Inference. Applied and Environmental Microbiology, 2020, 87, .	3.1	5
342	Unraveling the behavior of oral drug products inside the human gastrointestinal tract using the aspiration technique: History, methodology and applications. European Journal of Pharmaceutical Sciences, 2020, 155, 105517.	4.0	18
343	Toward Developing Discriminating Dissolution Methods for Formulations Containing Nanoparticulates in Solution: The Impact of Particle Drift and Drug Activity in Solution. Molecular Pharmaceutics, 2020, 17, 4125-4140.	4.6	12
344	Effects of Coformer and Polymer on Particle Surface Solution-Mediated Phase Transformation of Cocrystals in Aqueous Media. Molecular Pharmaceutics, 2020, 17, 3825-3836.	4.6	28
345	A physiologically-based drug absorption modeling for orally disintegrating tablets. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 152, 1-9.	4.3	6
346	A dual pH and microbiota-triggered coating (Phloralâ"¢) for fail-safe colonic drug release. International Journal of Pharmaceutics, 2020, 583, 119379.	5.2	58
348	Do Aspirin and Flavonoids Prevent Cancer through a Common Mechanism Involving Hydroxybenzoic Acids?—The Metabolite Hypothesis. Molecules, 2020, 25, 2243.	3.8	14
349	Evaluation of Differences in Dosage Form Performance of Generics Using BCS-Based Biowaiver Specifications and Biopharmaceutical Modeling–Case Examples Amoxicillin and Doxycycline. Journal of Pharmaceutical Sciences, 2020, 109, 2437-2453.	3.3	10
350	The tangential flow absorption model (TFAM) – A novel dissolution method for evaluating the performance of amorphous solid dispersions of poorly water-soluble actives. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 154, 74-88.	4.3	2

#	Article	IF	CITATIONS
351	Solubility of bisacodyl in fourteen mono solvents and N-methyl-2-pyrrolidoneÂ+Âwater mixed solvents at different temperatures, and its application for nanosuspension formation using liquid antisolvent precipitation. Journal of Molecular Liquids, 2020, 310, 113264.	4.9	30
352	The Use of Capsule Endoscopy to Determine Tablet Disintegration In Vivo. Pharmaceutics, 2020, 12, 498.	4.5	8
353	Kiwifruit drives human microbiota-derived DNA to stimulate IL-7 secretion in intestinal epithelial cells. Journal of Functional Foods, 2020, 67, 103882.	3.4	3
354	Impact of gastrointestinal physiology on drug absorption in special populations––An UNGAP review. European Journal of Pharmaceutical Sciences, 2020, 147, 105280.	4.0	142
355	Exploring the Potential of Hydrophilic Matrix Combined with Insoluble Film Coating: Preparation and Evaluation of Ambroxol Hydrochloride Extended Release Tablets. AAPS PharmSciTech, 2020, 21, 93.	3.3	6
356	Therapy for the individual: Towards patient integration into the manufacturing and provision of pharmaceuticals. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 149, 58-76.	4.3	37
357	Gastrointestinal Tracking and Gastric Emptying of Coated Capsules in Rats with or without Sedation Using CT imaging. Pharmaceutics, 2020, 12, 81.	4.5	20
358	Insight into the colonic disposition of celecoxib in humans. European Journal of Pharmaceutical Sciences, 2020, 145, 105242.	4.0	12
359	Solution-mediated phase transformation at particle surface during cocrystal dissolution. Journal of Drug Delivery Science and Technology, 2020, 56, 101566.	3.0	20
360	OPTICOREâ,,¢, an innovative and accurate colonic targeting technology. International Journal of Pharmaceutics, 2020, 583, 119372.	5.2	46
361	Biotransformed grape pomace as a potential source of anti-inflammatory polyphenolics: Effects in Caco-2Âcells. Food Bioscience, 2020, 35, 100607.	4.4	19
362	Similarity of dissolution profiles from biorelevant media: Assessment of interday repeatability, interanalyst repeatability, and interlaboratory reproducibility using ibuprofen and ketoconazole tablets. European Journal of Pharmaceutical Sciences, 2021, 156, 105573.	4.0	14
363	Applications of Polymers in Colon Drug Delivery. , 2021, , 187-220.		1
364	The Provisional No-Effect Threshold of Sugar Alcohols on Oral Drug Absorption Estimated by Physiologically Based Biopharmaceutics Model. Journal of Pharmaceutical Sciences, 2021, 110, 467-477.	3.3	11
365	InÂVitro Biopredictive Methods: A Workshop Summary Report. Journal of Pharmaceutical Sciences, 2021, 110, 567-583.	3.3	18
366	Predicting the environmental emissions arising from conventional and nanotechnology-related pharmaceutical drug products. Environmental Research, 2021, 192, 110219.	7.5	12
367	Insight into the Colonic Disposition of Sulindac in Humans. Journal of Pharmaceutical Sciences, 2021, 110, 259-267.	3.3	9
368	Characteristics of Contents of Lower intestine in the 65–74ÂYears of Age Range Could Impact the Performance of Safe and Efficacious Modified Release Products. Journal of Pharmaceutical Sciences, 2021, 110, 251-258.	3.3	9

#	Article	IF	CITATIONS
369	Leveraging bile solubilization of poorly water-soluble drugs by rational polymer selection. Journal of Controlled Release, 2021, 330, 36-48.	9.9	14
370	Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Support Waivers of <i>In Vivo</i> Clinical Studies: Current Status, Challenges, and Opportunities. Molecular Pharmaceutics, 2021, 18, 1-17.	4.6	9
371	Ectoines as novel anti-inflammatory and tissue protective lead compounds with special focus on inflammatory bowel disease and lung inflammation. Pharmacological Research, 2021, 164, 105389.	7.1	8
372	Intestinal permeation enhancers to improve oral bioavailability of macromolecules: reasons for low efficacy in humans. Expert Opinion on Drug Delivery, 2021, 18, 273-300.	5.0	36
373	Oral Drug Delivery, Absorption and Bioavailability. , 2022, , 406-437.		3
374	Drug Disposition in the Lower Gastrointestinal Tract: Targeting and Monitoring. Pharmaceutics, 2021, 13, 161.	4.5	18
375	Understanding Mechanisms of Food Effect and Developing Reliable PBPK Models Using a Middle-out Approach. AAPS Journal, 2021, 23, 12.	4.4	23
376	New Pharmaceutical Salts of Trazodone. Molecules, 2021, 26, 769.	3.8	1
377	Current State and Future Expectations of Translational Modeling Strategies to Support Drug Product Development, Manufacturing Changes and Controls: A Workshop Summary Report. Journal of Pharmaceutical Sciences, 2021, 110, 555-566.	3.3	36
378	Transepithelial Anti-Neuroblastoma Response to Kale among Four Vegetable Juices Using In Vitro Model Co-Culture System. Nutrients, 2021, 13, 488.	4.1	4
379	Amorphous Drug–Polymer Salt with High Stability under Tropical Conditions and Fast Dissolution: The Case of Clofazimine and Poly(acrylic acid). Molecular Pharmaceutics, 2021, 18, 1364-1372.	4.6	21
380	Lost in modelling and simulation?. ADMET and DMPK, 2021, 9, 75-109.	2.1	21
381	Dose-Dependent Solubility–Permeability Interplay for Poorly Soluble Drugs under Non-Sink Conditions. Pharmaceutics, 2021, 13, 323.	4.5	6
382	Short communication: Evaluating the recovery potential of injured cells of Listeria innocua under product temperature-abuse conditions and passage through simulated gastrointestinal fluids. Journal of Dairy Science, 2021, 104, 2787-2793.	3.4	0
383	Sustained-release hot melt extrudates of the weak acid TMP-001: A case study using PBB modelling. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 160, 23-34.	4.3	4
384	Physiologically Based Biopharmaceutics Modeling of Regional and Colon Absorption in Dogs. Molecular Pharmaceutics, 2021, 18, 1699-1710.	4.6	9
385	Organic Cation Transporter 1 an Intestinal Uptake Transporter: Fact or Fiction?. Frontiers in Pharmacology, 2021, 12, 648388.	3.5	9
386	In vitro interactions of Alternaria mycotoxins, an emerging class of food contaminants, with the gut microbiota: a bidirectional relationship. Archives of Toxicology, 2021, 95, 2533-2549.	4.2	12

#	Article	IF	CITATIONS
387	Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network. Advanced Drug Delivery Reviews, 2021, 171, 289-331.	13.7	84
388	Current Film Coating Designs for Colon-Targeted Oral Delivery. Current Medicinal Chemistry, 2021, 28, 1957-1969.	2.4	5
389	Exploring clinically relevant dissolution specifications for oral solid dosage forms of weak acid drugs using an in silico modeling and simulation approach. European Journal of Pharmaceutical Sciences, 2021, 159, 105728.	4.0	4
390	Oral delivery of micro/nanoparticulate systems based on natural polysaccharides for intestinal diseases therapy: Challenges, advances and future perspectives. Journal of Controlled Release, 2021, 334, 353-366.	9.9	61
391	Effect of gastrointestinal transit on micro-environmental pH inside HPMC matrix tablets – in vitro study. International Journal of Pharmaceutics, 2021, 604, 120718.	5.2	3
392	Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review. European Journal of Pharmaceutical Sciences, 2021, 162, 105812.	4.0	137
393	Do Macrocyclic Peptide Drugs Interact with Bile Salts under Simulated Gastrointestinal Conditions?. Molecular Pharmaceutics, 2021, 18, 3086-3098.	4.6	4
394	Controlling drug release with additive manufacturing-based solutions. Advanced Drug Delivery Reviews, 2021, 174, 369-386.	13.7	33
395	Evaluating the Impact of Physiological Properties of the Gastrointestinal Tract On Drug In Vivo Performance Using Physiologically Based Biopharmaceutics Modeling and Virtual Clinical Trials. Journal of Pharmaceutical Sciences, 2021, 110, 3069-3081.	3.3	6
396	Towards Virtual Bioequivalence Studies for Oral Dosage Forms Containing Poorly Water-Soluble Drugs: A Physiologically Based Biopharmaceutics Modeling (PBBM) Approach. Journal of Pharmaceutical Sciences, 2022, 111, 135-145.	3.3	8
397	Colonic delivery of metronidazole-loaded capsules for local treatment of bacterial infections: A clinical pharmacoscintigraphy study. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 165, 22-30.	4.3	8
399	A New Dose-Response Model for Estimating the Infection Probability of Campylobacter jejuni Based on the Key Events Dose-Response Framework. Applied and Environmental Microbiology, 2021, 87, e0129921.	3.1	5
400	Formulation strategies to improve the efficacy of intestinal permeation enhancers,. Advanced Drug Delivery Reviews, 2021, 177, 113925.	13.7	39
401	Potential pharmacokinetic interaction between orally administered drug and osmotically active excipients in pediatric polypharmacy. European Journal of Pharmaceutical Sciences, 2021, 165, 105934.	4.0	2
402	New biphasic system in side-by-side chambers for testing drug dissolution and permeation in vitro (BiDP system). Journal of Drug Delivery Science and Technology, 2021, 65, 102747.	3.0	1
403	Inhibition of α-glucosidases by tea polyphenols in rat intestinal extract and Caco-2 cells grown on Transwell. Food Chemistry, 2021, 361, 130047.	8.2	26
404	In vitro models to evaluate ingestible devices: Present status and current trends. Advanced Drug Delivery Reviews, 2021, 178, 113924.	13.7	11
406	Recent Update on Nanomedicine-Based Drug Targeting on Colon Cancer. , 2021, , 303-332.		0

# 409	ARTICLE Paediatric Development: Gastrointestinal. AAPS Advances in the Pharmaceutical Sciences Series, 2014, ,	IF 0.6	Citations
410	Impact of Excipient Interactions on Drug Bioavailability from Solid Dosage Forms. , 2015, , 273-310.		2
411	Solid Lipid Excipients as Matrix Agents for Sustained Drug Delivery. , 2015, , 237-271.		9
412	Modelling and simulation of the hydrodynamics and mixing profiles in the human proximal colon using Discrete Multiphysics. Computers in Biology and Medicine, 2020, 121, 103819.	7.0	21
413	Colon-Specific Delivery of Bioactive Agents Using Genipin-Cross-Linked Chitosan Coated Microcontainers. ACS Applied Bio Materials, 2021, 4, 752-762.	4.6	19
415	Effects of genetic polymorphisms on the OCT1 and OCT2-mediated uptake of ranitidine. PLoS ONE, 2017, 12, e0189521.	2.5	32
416	An extract from date palm fruit (Phoenix dactylifera) acts as a co-agonist ligand for the nuclear receptor FXR and differentially modulates FXR target-gene expression in vitro. PLoS ONE, 2018, 13, e0190210.	2.5	20
417	Measurement of fasted state gastric antral motility before and after a standard bioavailability and bioequivalence 240 mL drink of water: Validation of MRI method against concomitant perfused manometry in healthy participants. PLoS ONE, 2020, 15, e0241441.	2.5	8
418	Investigation of the Dissolution Characteristics of Nifedipine Extended-Release Formulations Using USP Apparatus 2 and a Novel Dissolution Apparatus. Dissolution Technologies, 2009, 16, 6-13.	0.6	8
420	Aspirin metabolites 2,3‑DHBA and 2,5‑DHBA inhibit cancer cell growth: Implications in colorectal cancer prevention. Molecular Medicine Reports, 2020, 21, 20-34.	2.4	14
421	Preparation and optimization of polymeric micelles as an oral drug delivery system for deferoxamine mesylate: in vitro and ex vivo studies. Research in Pharmaceutical Sciences, 2019, 14, 293.	1.8	36
422	Exploring the impact of Crohn's disease on the intragastric environment of fasted adults. ADMET and DMPK, 2020, 8, 122.	2.1	4
423	Oral biomaterials for intestinal regulation. Engineered Regeneration, 2021, 2, 116-132.	6.0	6
424	Quantification of Fluid Volume and Distribution in the Paediatric Colon via Magnetic Resonance Imaging. Pharmaceutics, 2021, 13, 1729.	4.5	5
425	Health food product composition, structure and bioavailability. , 2009, , 647-675.		2
428	Physiological Factors Affecting Drug Release and Absorption in the. , 2016, , 17-36.		0
429	In Vivo Characterization of Oral Multiparticulate Systems. Advances in Delivery Science and Technology, 2017, , 359-386.	0.4	0
430	Dissolution Test Considerations for Oral Multiparticulate Systems. Advances in Delivery Science and Technology, 2017, , 169-212.	0.4	1

ARTICLE IF CITATIONS Chapter 14 Dissolution Testing of Poorly Soluble Drugs: "Biorelevant Dissolutionâ€, 2017, 455-510. 431 0 Colonic Drug Delivery Systems as Multiunit Potential: Therapeutic Strategies and Opportunities., 2019, , 151-181. Permeation characteristics of tetracyclines in parallel artificial membrane permeation assay II: Effect 433 2.1 3 of divalent metal ions and mucin. ADMET and DMPK, 2020, 8, 129-138. Mechanistic modeling of gastrointestinal motility with integrated dissolution for simulating drug 434 absorption. ADMET and DMPK, 2020, 8, 314-324. Small bowel water content assessed by MRI in health and disease: a collation of singleâ \in centre studies. 435 3.7 6 Alimentary Pharmacology and Therapeutics, 2022, 55, 327-338. Enteral Medication for the Tubeâ€Fed Patient: Making This Route Safe and Effective. Nutrition in Clinical 2.4 Practice, 2021, 36, 111-132. A target fishing study to spot possible biological targets of fusaric acid: Inhibition of protein kinase-A 437 3.6 6 and insights on the underpinning mechanisms. Food and Chemical Toxicology, 2022, 159, 112663. The Effect of Capsule-in-Capsule Combinations on In Vivo Disintegration in Human Volunteers: A 4.5 10 Combined Imaging and Salivary Tracer Study. Pharmaceutics, 2021, 13, 2002. Review of paediatric gastrointestinal physiology relevant to the absorption of orally administered medicines. Advanced Drug Delivery Reviews, 2022, 181, 114084. 440 13.7 26 Clinical translation of advanced colonic drug delivery technologies. Advanced Drug Delivery 441 13.7 Reviews, 2022, 181, 114076. Investigation of the effect of verapamil on the regional absorption of sofosbuvir from rabbit 442 0 2.0 intestine in situ. DARU, Journal of Pharmaceutical Sciences, 2022, , 1. Application of In Vivo MRI Imaging to Track a Coated Capsule and Its Disintegration in the 4.5 Gastrointestinal Tract in Human Volunteers. Pharmaceutics, 2022, 14, 270. In Vitro Methodologies for Evaluating Colon-Targeted Pharmaceutical Products and Industry 444 4.5 10 Perspectives for Their Applications. Pharmaceutics, 2022, 14, 291. Polymeric precipitation inhibitor differently affects cocrystal surface and bulk solution phase transformations. Journal of Drug Delivery Science and Technology, 2022, 67, 103029. 445 Effect of ingested fluid volume and solution osmolality on intestinal drug absorption: Impact on 447 4.0 7 drug interaction with beverages. European Journal of Pharmaceutical Sciences, 2022, 172, 106136. Application of In Vivo Imaging Techniques and Diagnostic Tools in Oral Drug Delivery Research. Pharmaceutics, 2022, 14, 801. The effect of esomeprazole on the upper GI tract release and systemic absorption of mesalazine from 458 5.23 colon targeted formulations. International Journal of Pharmaceutics, 2022, 619, 121701. Dissolution Kinetics of Nifedipineâ€"Ionizable Polymer Amorphous Solid Dispersion: Comparison Between Bicarbonate and Phosphate Buffers. Pharmaceutical Research, 2021, 38, 2119-2127.

#	Article	IF	CITATIONS
462	<i>Alternaria alternata</i> Mycotoxins Activate the Aryl Hydrocarbon Receptor and Nrf2-ARE Pathway to Alter the Structure and Immune Response of Colon Epithelial Cells. Chemical Research in Toxicology, 2022, 35, 731-749.	3.3	7
463	A Critical Overview of the Biological Effects of Excipients (Part II): Scientific Considerations and Tools for Oral Product Development. AAPS Journal, 2022, 24, 61.	4.4	2
464	Modeling the invasion of human small intestinal epithelialâ€like cells by <i>Salmonella enterica</i> Typhimurium and <i>Listeria monocytogenes</i> using Bayesian inference. Letters in Applied Microbiology, 2022, , .	2.2	0
465	The Use of Physiologically Based Pharmacokinetic Analyses—in Biopharmaceutics Applications -Regulatory and Industry Perspectives. Pharmaceutical Research, 2022, 39, 1681-1700.	3.5	16
466	Efficient Evaluation of In Vivo Performance in Human for Generic Formulation by Novel Dissolution-Absorption Prediction (DAP) Workflow. Pharmaceutical Research, 2022, 39, 2203-2216.	3.5	1
467	Biological and intracellular fates of drug nanocrystals through different delivery routes: Recent development enabled by bioimaging and PK modeling. Advanced Drug Delivery Reviews, 2022, 188, 114466.	13.7	17
468	Physiologically Based Biopharmaceutics Model for Selumetinib Food Effect Investigation and Capsule Dissolution Safe Space – Part I: Adults. Pharmaceutical Research, 2023, 40, 387-403.	3.5	5
469	Colonic Delivery of Nutrients for Sustained and Prolonged Release of Gut Peptides: A Novel Strategy for Appetite Management. Molecular Nutrition and Food Research, 2022, 66, .	3.3	2
470	Bioavailability-Enhancing Cocrystals: Screening, <i>In Vivo</i> Predictive Dissolution, and Supersaturation Maintenance. Crystal Growth and Design, 2022, 22, 5154-5167.	3.0	4
471	Targeted colonic release formulations of mesalazine – A clinical pharmaco-scintigraphic proof-of-concept study in healthy subjects and patients with mildly active ulcerative colitis. International Journal of Pharmaceutics, 2022, 625, 122055.	5.2	7
472	Gastrointestinal Fluid Volumes in Pediatrics: A Retrospective MRI Study. Pharmaceutics, 2022, 14, 1935.	4.5	9
473	Quantitative assessment of disintegration rate is important for predicting the oral absorption of solid dosage forms containing poorly soluble weak base drugs. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 180, 23-32.	4.3	1
474	A doxycycline-inducible CYP3A4-Caco-2 cell line as a model for evaluating safety of aflatoxin B1 in the human intestine. Toxicology Letters, 2022, 370, 1-6.	0.8	2
475	A biopharmaceutics perspective on oral peptide developability and drug delivery. , 2022, , 87-130.		0
476	Fast-Fed Variability: Insights into Drug Delivery, Molecular Manifestations, and Regulatory Aspects. Pharmaceutics, 2022, 14, 1807.	4.5	5
477	Improved Bioavailability and Bioaccessibility of Lutein and Isoflavones in Cultured Cells In Vitro through Interaction with Ginger, Curcuma and Black Pepper Extracts. Antioxidants, 2022, 11, 1917.	5.1	2
478	Development of a multiparticulate drug delivery system for in situ amorphisation. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 180, 170-180.	4.3	5
479	Patient-specific in vitro drug release testing coupled with in silico PBPK modeling to forecast the in vivo performance of oral extended-release levodopa formulations in Parkinson's disease patients. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 180, 101-118.	4.3	4

#	Article	IF	CITATIONS
480	Dynamic Changes in Gastrointestinal Fluid Characteristics after Food Ingestion Are Important for Quantitatively Predicting the <i>In Vivo</i> Performance of Oral Solid Dosage Forms in Humans in the Fed State. Molecular Pharmaceutics, 0, , .	4.6	0
481	Colonic drug delivery: Formulating the next generation of colon-targeted therapeutics. Journal of Controlled Release, 2023, 353, 1107-1126.	9.9	36
482	SNAC for Enhanced Oral Bioavailability: An Updated Review. Pharmaceutical Research, 2023, 40, 633-650.	3.5	7
483	Plant polysaccharides for colon-targeted drug delivery. , 2023, , 329-368.		0
484	Physiologically based biopharmaceutics modeling of regional and colon absorption in humans. European Journal of Pharmaceutics and Biopharmaceutics, 2023, 186, 144-159.	4.3	5
485	Location-aware ingestible microdevices for wireless monitoring of gastrointestinal dynamics. Nature Electronics, 2023, 6, 242-256.	26.0	24
486	PhysioCell®; — a Novel, Bio-relevant Dissolution Apparatus: Hydrodynamic Conditions and Factors Influencing the Dissolution Dynamics. AAPS PharmSciTech, 2023, 24, .	3.3	2
487	Delivery of a therapeutic antibody to the lower gastrointestinal tract for the treatment of <i>Clostridium difficile</i> infection (CDI). Pharmaceutical Development and Technology, 2023, 28, 232-239.	2.4	0
488	Acalabrutinib Maleate Tablets: The Physiologically Based Biopharmaceutics Model behind the Drug Product Dissolution Specification. Molecular Pharmaceutics, 2023, 20, 2181-2193.	4.6	3
489	Nanoplastics Weathering and Polycyclic Aromatic Hydrocarbon Mobilization. ACS Nano, 2023, 17, 5773-5784.	14.6	2
490	Oral administration of PET tracers: Current status. Journal of Controlled Release, 2023, 357, 591-605.	9.9	0
491	Oral bioavailability of bioactive compounds; modulating factors, <i>in vitro</i> analysis methods, and enhancing strategies. Critical Reviews in Food Science and Nutrition, 0, , 1-39.	10.3	4
492	Physiologically Based Pharmacokinetic (PBPK) Modeling Application on Food Effect Assessment. AAPS Introductions in the Pharmaceutical Sciences, 2023, , 29-56.	0.1	0
493	Phosphate buffer interferes dissolution of prazosin hydrochloride in compendial dissolution testing. Drug Metabolism and Pharmacokinetics, 2023, 51, 100519.	2.2	1
494	Physiologically Based Pharmacokinetic (PBPK) Modelling of Oral Drug Absorption in Older Adults – an AGePOP review. European Journal of Pharmaceutical Sciences, 2023, , 106496.	4.0	2
495	Stochastic Differential Equation-based Mixed Effects Model of the Fluid Volume in the Fasted Stomach in Healthy Adult Human. AAPS Journal, 2023, 25, .	4.4	2
496	Selective COX-2 inhibitors after bariatric surgery: Celecoxib, etoricoxib and etodolac post-bariatric solubility/dissolution and pharmacokinetics. International Journal of Pharmaceutics, 2023, , 123347.	5.2	1
497	Challenges in Permeability Assessment for Oral Drug Product Development. Pharmaceutics, 2023, 15, 2397.	4.5	1

#	Article	IF	CITATIONS
498	Safety of surfactant excipients in oral drug formulations. Advanced Drug Delivery Reviews, 2023, 202, 115086.	13.7	2
499	Bioavailability and Bioequivalence. , 2024, , 517-535.		Ο
500	Physiological Dynamics in the Upper Gastrointestinal Tract and the Development of Gastrointestinal Absorption Models for the Immediate-Release Oral Dosage Forms in Healthy Adult Human. Pharmaceutical Research, 2023, 40, 2607-2626.	3.5	1
501	Quantitative analysis of gastrointestinal fluid absorption and secretion to estimate luminal fluid dynamics in rats. Scientific Reports, 2023, 13, .	3.3	Ο
502	A toolbox for mimicking gastrointestinal conditions in children: Design and evaluation of biorelevant dissolution media for mimicking paediatric gastric- and small intestinal conditions. European Journal of Pharmaceutics and Biopharmaceutics, 2023, , .	4.3	0
503	Modeling of the Aqueous Solubility of N-butyl-N-methyl-1-phenylpyrrolo[1,2-a] pyrazine-3-carboxamide: From Micronization to Creation of Amorphous–Crystalline Composites with a Polymer. Polymers, 2023, 15, 4136.	4.5	0
504	Intestinal retentive systems $\hat{a} \in ``$ recent advances and emerging approaches. Journal of Materials Chemistry B, O, , .	5.8	0
505	Development of Sustained Release System Based on High Water-Absorbable Gel Formation Using Croscarmellose Sodium, Alkaline Excipients and HPMC (ACSH SR System); Novel Application of Croscarmellose Sodium as a Gel Former. Pharmaceutical Research, 2023, 40, 3073-3086.	3.5	0
506	Approaches to Account for Colon Absorption in Physiologically Based Biopharmaceutics Modeling of Extended-Release Drug Products. Molecular Pharmaceutics, 2023, 20, 6272-6288.	4.6	0
507	Aerogels as Carriers for Oral Administration of Drugs: An Approach towards Colonic Delivery. Pharmaceutics, 2023, 15, 2639.	4.5	1
508	Potassium homeostasis and therapeutic intervention with sodium zirconium cyclosilicate: A <scp>modelâ€informed</scp> drug development case study. CPT: Pharmacometrics and Systems Pharmacology, 2024, 13, 296-307.	2.5	0
512	The Complexity of Bariatric Patient's Pharmacotherapy: Sildenafil Biopharmaceutics and Pharmacokinetics before vs. after Gastric Sleeve/Bypass. Pharmaceutics, 2023, 15, 2795.	4.5	0
513	Understanding the Conditions Under Which Drugs are Transferred from the Stomach Through the Upper Small Intestine After a High-Calorie, High-Fat Meal. Journal of Pharmaceutical Sciences, 2024, , .	3.3	0
516	In silico, in situ, in vitro, and in vivo predictive methods for modeling formulation performance. , 2024, , 67-116.		0
517	Colonic disorder management: challenges and prospects. , 2024, , 385-406.		0
518	Dynamics and metabolic effects of intestinal gases in healthy humans. Biochimie, 2024, 221, 81-90.	2.6	0
519	Antibiotic Residues in UK Foods: Exploring the Exposure Pathways and Associated Health Risks. Toxics, 2024, 12, 174.	3.7	0
520	Pine nut skin as a source of phytosterols and alkanediols - Hypocholesterolemic potential and development of sustainable vegan emulsifiers. LWT - Food Science and Technology, <u>2024, 197, 115934.</u>	5.2	0

#	Article	IF	CITATIONS
521	Use of Magnetic Resonance Imaging for Visualization of Oral Dosage Forms in the Human Stomach: A Scoping Review. Molecular Pharmaceutics, 2024, 21, 1553-1562.	4.6	0
522	Current Advances of Nanomaterial-Based Oral Drug Delivery for Colorectal Cancer Treatment. Nanomaterials, 2024, 14, 557.	4.1	0